Why Cancer Staging Matters Before Treatment Begins

It is not available for everyone blanketly — you first need to identify the target on the cell, which is where NGS and special staining come in. Not every individual harbours those targets, but many do, and we then use specific targeted drugs. Immunotherapy is not available for all cancers either, but with present indications it is available for the majority of advanced cancers — about 70% of advanced cancers would be candidates for some form of immunotherapy. There are specific criteria that must be met; giving it without meeting those criteria would not help the patient and would just be a financial waste.

We take a biopsy from the specimen, cut it into sections, make blocks, and apply immunohistochemistry staining, which lets us identify targets on the cells. We then do mutation testing to see what mutations are present in the genes, to identify further targets we can address. We also do PD-L1 testing, which tells us whether the patient can receive immunotherapy. It is a combination of these staining protocols along with NGS that tells us the best way forward for the patient.

We take the biopsy specimen and extract the DNA from the cancer cell, then sequence it to identify where something has gone wrong in the DNA or RNA, which tells us why that individual developed the cancer. Through this we identify specific mutations that may be the probable reason. Research is ongoing to counteract every change found on NGS, but currently we have a few drugs available for certain specific mutations — if we find one of those, we give that specific drug and the patient benefits.

If you don't have a PET-CT, the second-best modality is a CT scan of the probable areas — chest, abdomen, and maybe head and neck depending on the cancer — which will give some answers on staging. As for treatment: chemotherapy is calculated as per the height, weight and profile of the patient, not given as a simple fixed dose. There are specific mixing criteria — it cannot be mixed like an antibiotic — and India has specific mixing units where care is taken over contamination and dosing. Drugs also have to be given over an appropriate infusion time, since infusing over the wrong duration causes more side effects. We also have monitoring systems running during chemotherapy to catch problems early, and targeted therapies and immunotherapies have specific temperature and light-sensitivity handling requirements that are important to follow correctly.

Previously it used to take 30 days, and it still does in most institutes, but with the advanced machines we now have, our turnaround time is only about five to six working days — even including a Sunday, a comprehensive NGS report is usually ready by about the seventh day.

Stage 1 is very early and localised, stage 2 is early but still local, stage 3 is locally advanced, and stage 4 means the cancer has spread beyond its site of origin, with each stage carrying a different treatment approach and expected outcome.

Because a diagnosis alone does not indicate whether surgery, medical therapy, radiation or a combination is appropriate. Patients who undergo surgery at stage 4 before the extent of disease is understood often find it does not help and simply delays effective treatment.

Once staging is complete, the treatment plan is built around the specific combination of cancer type, site and stage rather than a generic approach, ensuring each patient receives the treatment actually indicated for their disease.